Cutaneous pruritus
Conditions
Interventions
Group A:Olopatadine 5mg, oral taken twice daily for 2 week
Group B:Cetirizine 10mg, oral taken once daily for 2 weeks
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 18-65 years old; 2. All the participants were in agreement with the CP criteria and the severity of patient itching was evaluated by using a standardized scale (i.e., 0 = no itching; 6 = severe itching); 3. The symptom score was greater than or equal to 3.
Exclusion criteria
Exclusion criteria: 1. Gravid and or lactating female (women of child-bearing period also underwent a urinary pregnancy test when necessary); 2. Workers under a high risk or drivers; subjects participating in another clinical trial or having participated in one in the last 3 months; 3. Patients that had organic heart diseases, arrhythmia and electrocardiographic abnormality; 4. Liver or renal function abnormality; 5. Patients that had been allergic to the study medication or the control; or a clinically significant abnormality, i.e., patients with malignance or who had a myocardial infarction or used sedative and ataractic medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptom score reducing index (SSRI); | — |
Secondary
| Measure | Time frame |
|---|---|
| The global efficact; | — |
Countries
China
Contacts
Public ContactJia Yin, Yuehua Liu
Outcome results
None listed